Drugs / HB0030
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05706207 | Dec 2021 → Sep 2023 | neoplasm | Huabo Biopharm Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HB0030 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05706207 ↗ |
| Modality | Monoclonal antibody | “Recombinant Humanized Anti-TIGIT Monoclonal Antibody” NCT05706207 ↗ |
| Route | Intravenous | “administered intravenously” NCT05706207 ↗ |